- Positive feedback from pre-IND meeting with FDA confirms Hikma’s continued development of AT307 under the 505(b)(2) regulatory pathway - Abbreviated 505(b)(2) submission offers an efficient and streamlined development pathway with reduced risk Cambridge, UK, 7th September 2023: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today’s therapies to enable healthier lives, is pleased to announce further progress from Hikma in the development of ready-to-use ("RTU") injectable medicine AT307, following a recent positive pre-investigational new drug…

Read the September edition of eNews here, featuring: ► Welcome from Tony Jones, CEO ► What is the Importance of Training and Developing Your Workforce? ► Why is Working for a One Nucleus Member Company Good for You? ► Revitalising Conference Websites: Enhancing Engagement for Life Science Companies ► Are You Asking the Right Questions when Assessing Your Next Lab Space? ► New Horizons in Genetic Screening    

  One Nucleus and GTM Global Enter into Collaboration to Support Member International and Connectivity Cambridge and London, UK, 05 September 2023 One Nucleus, the leading Life Science membership group supporting the translation of bio-innovation into successful businesses and ultimately patient benefit is delighted to announce the collaborative partnership with GTM Global (GTM), the unique online interactive ecosystem that engages with ambitious tech and digital scale-up businesses to expand internationally. One Nucleus members will be able access GTM’s high-touch programme of…

Sign up to receive the latest regulatory updates from Boyds: https://boydconsultants.com/sign-up/ In this month's newsletter they shared recent guidance and key updates from the regulatory agencies: Food and Drug Association (FDA)​ European Medicines Agency (EMA) Medicines and Healthcare products Regulatory Agency (MHRA) European Commission (EC) World Health Organisation (WHO)   On 5 October, Boyds is hosting a free webinar on 'How to successfully operationalize real-world data collection alongside expanded access programs', for more info and how to sign up, click here.

More than half the Cambridge startups [60.7%] listed in Seedtable’s ‘Startups in Cambridge to Watch’ list last month [July 2023] have already appeared on cofinitive’s #21toWatch list in previous years. This timely revelation, as the nominations window for #21toWatch 2024 opens, confirms that the #21toWatch awards really do spotlight the brightest and best from across Cambridge and beyond. #21toWatch recognises the outstanding people, companies and innovations in our region, providing high-level exposure and increasing opportunities for funding and investment for the winning candidates. Every…

Check out and subscribe to the latest newsletter from Stevenage Bioscience Catalyst. Highlights include:  UBS Asset Management and Reef Group secure approval for one of Europe's largest Life Sciences campuses in Europe Cell and Gene Therapy, Rentschler Biopharma and Refeyn collaborate to improve process analytical technologies and AAV manufacturing for gene therapies Plasticell, Cell and Gene Therapy Catapult and Imperial College London obtain funding to develop manufacturing platform for allogenic cell immunotherapies BioWednesday Stevenage: 6 September

In the latest edition of the Penningtons Manches Cooper LLP BioBrief newsletter, their team explores university-generated IP and in particular what it means for students who are involved and contributing to such IP... Read more.

Lab-on-chip technology for screening live tumor Glasgow, UK based – ScreenIn3D reports on how their proprietary lab-on-a-chip technology is enabling cancer researchers to miniaturize their testing of biopsy tissue samples across a wide range of modalities and to test both single and combination drug therapies on live tissue samples. Combining the latest advances in microfluidics and 3D cell culture – ScreenIn3D’s unique chip technology enables researchers to use as few as 1000 cells for tens of 3D cancer screening experiments. ScreenIn3D has recently secured investment…

Cambridge, UK, 30th August 2023: CN Bio, a leading Organ-on-a-Chip (OOC) company that designs and manufactures single-and multi-organ microphysiological systems (MPS), today announced the appointment of Dr. Tomasz Kostrzewski as Chief Scientific Officer. Previously Vice President of Science and Technology, Dr. Kostrzewski’s promotion creates a new position in CN Bio’s leadership team, marking another key milestone in the Company’s development as the fourth leadership-level appointment within the past year. Dr. Kostrzewski has more than 15 years of experience in molecular and cellular biology…

Cambridge, UK / Waltham, MA, August 28, 2023 – Abcam plc (Nasdaq: ABCM) (‘Abcam’, the ‘Group’ or the ‘Company’), a global leader in the supply of life science research tools, announced today that it has entered into a definitive agreement pursuant to which Danaher Corporation (NYSE: DHR) (‘Danaher’) will acquire all of the outstanding shares of Abcam for $24.00 per share in cash (the ‘Transaction’).  The Transaction has been unanimously approved and recommended by the Abcam Board of Directors and unanimously approved by the Danaher Board of Directors.  Founded in 1998 and…